Peregrine Announces Participation at Upcoming Investor Conferences
TUSTIN, CA -- (Marketwire) -- 02/26/13 -- Peregrine Pharmaceuticals,
Inc. (NASDAQ: PPHM), a biopharmaceutical company developing
first-in-class monoclonal antibodies focused on the treatment and
diagnosis of cancer, today announced that Steven W. King, president
and chief executive officer, will participate at the following
-- 33rd Annual Cowen Health Care Conference
Tuesday, March 5, 2013, at
10:40am Eastern Standard Time
Marriott Copley Hotel Boston,
-- 25th Annual ROTH Conference
Monday, March 18, 2013, at 2:00pm Pacific
The Ritz Carlton Hotel Dana Point, California
-- Stifel Nicolaus & Company Biotechnology Investor Day
March 20, 2013
San Francisco, California
Peregrine's presentations at the Cowen and Roth Conferences will be
webcast live and available for replay until April 12, 2013 and April
25, 2013, respectively at: http://ir.peregrineinc.com/events.cfm.
About Peregrine Pharmaceuticals, Inc.
Inc. is a biopharmaceutical company with a portfolio of innovative
monoclonal antibodies in clinical trials focused on the treatment and
diagnosis of cancer. The company is pursuing multiple clinical
programs in cancer with its lead product candidate bavituximab and
novel brain cancer agent Cotara(R). Peregrine also has in-house cGMP
manufacturing capabilities through its wholly-owned subsidiary Avid
Bioservices, Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and outside customers.
Additional information about Peregrine can be found at
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
Press spacebar to pause and continue. Press esc to stop.